Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic ...
Jacobio Pharmaceuticals presented glecirasib's efficacy in treating KRAS G12C mutated pancreatic and other solid tumors at ASCO GI 2024. With a 48% cORR and 90% DCR in evaluable patients, glecirasib shows promise over standard treatments, supported by safety and tolerability data. It received BTD for pancreatic cancer, aiming to expedite its development and patient access.
Reference News
Jacobio Pharmaceuticals announced glecirasib's efficacy in treating KRAS G12C mutated pancreatic and other solid tumors, showing a 48% response rate and 90% disease control rate. Glecirasib, with better safety and tolerance than chemotherapy, received breakthrough therapy designation, aiming to expedite treatment access for patients.
Jacobio Pharmaceuticals presented glecirasib's efficacy in treating KRAS G12C mutated pancreatic and other solid tumors at ASCO GI 2024. With a 48% cORR and 90% DCR in evaluable patients, glecirasib shows promise over standard treatments, supported by safety and tolerability data. It received BTD for pancreatic cancer, aiming to expedite its development and patient access.